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Hematopoietic Stem Cells
High number of circulating CD34+ cells in
patients with myelophthisis
Six patients with bone marrow micrometastases
from solid cancers presented with increased num-
bers of circulating CD34+ cells; the CD34+ cell
counts were very high in some cases. By contrast,
no patient with metastatic cancer without bone
marrow involvement showed raised numbers of
circulating hemopoietic progenitors.
haematologica 2005; 90:976-977
(http://www.haematologica.org/journal/2005/7/976.html)
The circulating CD34 (cCD34+) cell count is assessed
daily to monitor stem cell mobilization in patients under-
going stem cell harvest from peripheral blood. Another
condition with raised numbers of cCD34+ cells is  idio-
pathic myelofibrosis,1 a finding suggesting that a normal
bone marrow microenvironment is essential for the bind-
ing of CD34+ cells to stroma. Myelophthisis is a peculiar
bone marrow microenvironment alteration caused by the
presence of a high number of non-hematopoietic neo-
plastic cells,  impairing hematopoiesis by largely
unknown mechanisms. Space occupation is not the main
mechanism, since micrometastases do not colonize the
whole marrow; rather, marrow is usually hypocellular,
with some degree of fibrosis revealed at bone biopsy.2-3
We investigated the number of cCD34+ cells in patients
with myelophthisis. 
We studied eleven patients with diffuse metastatic can-
cer (Table 1). Myelophthisis was suspected in patients pre-
senting uni-, bi-, or trilineage cytopenia not due to
chemotherapy, and was documented by the finding of non-
hematopoietic neoplastic cells in a bone marrow aspirate
and/or biopsy. Peripheral blood, collected in K3EDTA, was
processed within 3 hours of venipuncture. CD34+ cells
were detected by a combination of two monoclonal anti-
bodies, fluorescein isothiocyanate-conjugated anti-CD45
and phycoerythrin-conjugated anti-CD34 (Becton
Dickinson, Boston, MA-USA); c-kit expression was also
measured. Fifty microliters of blood were incubated with
the antibodies for 20 min in tubes containing a known
number of microbeads. Cells were identified by
FACSCalibur (Becton Dickinson, Boston, MA, USA)
using scattering and fluorescence methods, and analyzed
following the sequential gating strategy recommended
by the International Society for Hematotherapy and
Graft Engineering (ISHAGE). To exclude any  influence of
drugs, patients were studied before or at least three
months after chemotherapy; none of the patients had
received growth factors.
Of the eleven patients with metastatic cancer of vari-
ous origin, six showed bone marrow micrometastases,
suggested by cytopenia and documented by bone aspi-
rate and/or biopsy, while five patients had no sign of
bone marrow involvement. Marrow fibrosis (surrounding
the metastatic lesions) was detected in the three patients
with myelophthisis who underwent bone biopsy.
cCD34+ (c-kit+) cell counts were elevated in all 6 patients
with myelophthisis, and were particularly high in  four..
In contrast, CD34+ cells were almost undetectable in the
patients with metastatic cancer without bone marrow
involvement (Table 1). The mean number of cCD34+ cells
was 49.2 and 1.2 cells/mL in the two groups, respectively.
Among patients suffering from various types of disorders
and tested for cCD34+ cells in our institution, the number
of cells detected was second highest in myelophthisis;
the highest number was found in idiopathic myelofibro-
sis (Figure 1).  
Stem cell mobilization by growth factors and/or
chemotherapy is caused by modifications of membrane-
bound molecules that enable detachment of cells from
the stroma. The only disease in which a high number of
cCD34+ cells has been described in the absence of any
treatment is idiopathic myelofibrosis;1,4,5 both an altered
bone marrow microenvironment and stem cell surface
Table 1. Circulating CD34+cells in metastatic cancer patients with or without bone marrow involvement.
Case Type of Blood count
Age Gender cancer Hb g/dL WBC N Plt Cancer Previous CD34+ /mL
¥109/L ¥109/L ¥109/L cells in therapy
bone marrow
1 46 F Breast 8.2 4.400 2.200 63 yes None 60.6
2 34 M Lung 7.9 5.310 3.240 163 yes Cis-platinum 19.4
3 53 F Stomach 8.4 17.000 14.620 49 yes None 48.2
4 66 M Lung 7.7 14.600 10.366 24 yes None 149.4
5 53 M Stomach 8.2 3.040 1.824 70 yes None 8.1
6 50 F Breast 9.4 15.500 7.500 51 yes None 9.7
7 71 M Stomach 11.1 6.410 4.295 265 5-FU 0
8 64 M Lung 14.7 7.790 6.465 199 Taxotere 4.0
9 59 M Lung 13.4 9.920 6.448 191 Cis-platinum 2.0
10 77 M Colon 13.8 3.930 2.974 95* 5-FU 0
11 64 M Stomach 11.9 8.600 6.450 237 5-FU 0
*: low count due to hypersplenism secondary to hepatitis C virus-related chronic hepatitis.
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abnormalities may underlie this phenomenon. A modest
increase of cCD34+ cells, attributed to granulocyte-mono-
cyte colony-stimulating factor (GM-CSF) production by
the neoplastic tissue, has been described in patients with
head or neck cancer.6 We found that patients harboring
cancer cells in the bone marrow had a mean of 49.2
cCD34+ cells/mL, 50 times  more than in patients with
metastatic cancer without bone marrow involvement.
This may be the consequence of various not mutually
exclusive mechanisms, including: (i) a stromal alteration,
evidenced in these patients by a frequent dry tap bone
marrow aspiration and some degree of fibrosis;2-3 (ii)
growth factors with mobilizing properties produced
locally by the neoplastic cells; (iii) local production of
molecules other than growth factors involved in stem cell
mobilization. As far as concerns this last possibility, it
could be relevant to note that a cleaved molecule of sol-
uble urokinase-type plasminogen activator (uPA) receptor
seems to be involved in both the metastasizing capacity
of cancer cells7 and in stem cell mobilization.8
Our series is too small to draw any conclusion on a
possible relation between degree of cytopenia and num-
ber of cCD34+ cells; the type of primary tumor does not
seem to be relevant. It is intriguing that two patients with
raised cCD34+ cell counts had low hemoglobin and
platelet levels but elevated neutrophil counts, suggesting
a common mechanisms for high cCD34+ and white cell
counts, as seen during mobilization. Several issues in this
setting need to be elucidated (e.g., cytokine levels in
blood and bone marrow, pattern of adhesion molecules
and in vitro growth of cCD34+cells). From a clinical point
of view, our observations  suggest that high cCD34+ cell
count may be indicative of bone marrow involvement in
patients with metastatic cancer.
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Red Cell Disorders
Association of the G-463A myeloperoxidase
polymorphism with infection in sickle cell anemia
Infections constitute a principal cause of morbid-
ity and mortality in sickle cell anemia (SCA). Here
we present evidence to suggest that a polymor-
phism (G-463A MPO) in the gene encoding the
myeloperoxidase (MPO) enzyme, important for the
host defense system, may significantly increase
susceptibility to infection in SCA. haematologica 2005; 90:977-979
(http://www.haematologica.org/journal/2005/7/977.html)
Sickle cell anemia is characterized by morphologically
abnormal red cells, vaso-occlusion with ischemic tissue
injury and susceptibility to infection. Infections, such as
pneumonia, osteomyelitis, meningitis, urinary infections
and septicemia, constitute a common cause of hospital-
ization in patients. While many patients have reduced
splenic function, the mechanisms that render SCA
patients more susceptible to infection are unclear. The
severity of SCA varies greatly between individuals and
this phenotypic variability is generally attributed to so-
called genetic modulators.1 Myeloperoxidase (MPO) is a
lysosomal enzyme found in neutrophils and monocytes
Figure 1. Circulating CD34+ cells in patients with metastatic can-
cer (with or without bone marrow involvement) or with various
types of myeloproliferative disorders. MF: idiopathic myelofibrosis;
MPhth: myelophthisis; MetCa: patients with diffuse metastatic
cancer without bone marrow involvement; ET: essential thrombo-
cythemia; PV: polycythemia vera; Ph- MPD: Philadelphia negative
myeloproliferative disorders; ST: secondary thrombocytosis; N: 10
healthy subjects; Mobilized N: normal subject mobilized by granu-
locyte colony-stimulating factor for allogeneic donation; Solid line:
upper limit in normal individuals.
